Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
RD-1302 by Nanjing Bioheng Biotech for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
RD-1302 is under clinical development by Nanjing Bioheng Biotech and currently in Phase I for Relapsed Acute Myeloid Leukemia. According...
Data Insights
RD-1302 by Nanjing Bioheng Biotech for Refractory Acute Myeloid Leukemia: Likelihood of Approval
RD-1302 is under clinical development by Nanjing Bioheng Biotech and currently in Phase I for Refractory Acute Myeloid Leukemia. According...